Get the Stockscreener App
1.44
2.13%
0.03
Pre-market:
1.49
0.05
+3.47%
Dogwood Therapeutics Inc stock is traded at $1.44, with a volume of 44,057.
It is up +2.13% in the last 24 hours and down -31.75% over the past month.
Dogwood Therapeutics Inc is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. The pipeline is focused on treating chronic neuropathic pain and neuropathy. The Company operates in one segment and is a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and peripheral neuropathy associated with cancer.
See More
Previous Close:
$1.41
Open:
$1.43
24h Volume:
44,057
Relative Volume:
0.56
Market Cap:
$48.10M
Revenue:
-
Net Income/Loss:
$-34.26M
P/E Ratio:
-0.0762
EPS:
-18.9056
Net Cash Flow:
$-15.62M
1W Performance:
+6.67%
1M Performance:
-31.75%
6M Performance:
-74.10%
1Y Performance:
-70.12%
1-Day Range:
$1.41
$1.47
1-Week Range:
$1.28
$1.54
52-Week Range:
$1.28
$9.50
Dogwood Therapeutics Inc Stock (DWTX) Company Profile
Name
Dogwood Therapeutics Inc
Sector
Industry
Phone
(866) 620-8655
Address
44 MILTON AVENUE, ALPHARETTA
Compare DWTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DWTX
Dogwood Therapeutics Inc
|
1.44 | 48.10M | 0 | -34.26M | -15.62M | -18.91 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dogwood Therapeutics Inc Stock (DWTX) Latest News
Dogwood Therapeutics Inc expected to post a loss of 26 cents a shareEarnings Preview - TradingView
Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX), NRX Pharmaceuticals (NRXP) and Immuneering (IMRX) - The Globe and Mail
[ARS] Dogwood Therapeutics, Inc. SEC Filing - Stock Titan
Big capital authorization vote ahead for Dogwood Therapeutics (NASDAQ: DWTX) - Stock Titan
Dogwood Therapeutics files to sell 28.04M shares of common stock for holders - MSN
Dogwood licenses IMC-1, IMC-2 antiviral assets to PRIDCor By Investing.com - Investing.com Canada
Dogwood licenses IMC-1, IMC-2 antiviral assets to PRIDCor - Investing.com
Dogwood Therapeutics Announces Worldwide Development and - GlobeNewswire
DWTX (Dogwood Therapeutics Inc.) posts far narrower Q4 2025 loss than consensus estimates, yet shares dip 4.47% today.Momentum Score - Cổng thông tin điện tử Tỉnh Sơn La
Dogwood Therapeutics, Inc. (DWTX) Advances SP16 Program with FDA Investigational New Drug Approval - Insider Monkey
5 Oversold Biotech Stocks to Invest In Now - Insider Monkey
Dogwood Therapeutics (DWTX) seeks approval to increase authorized shares to 195M - Stock Titan
Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy - Sahm
Dogwood Therapeutics receives FDA clearance for SP16 pain trial By Investing.com - Investing.com Australia
Dogwood Therapeutics, Inc (NASDAQ:DWTX) Sees Large Increase in Short Interest - MarketBeat
Dogwood Therapeutics receives FDA clearance for SP16 pain trial - Investing.com
Dogwood Therapeutics Announces FDA Acceptance of SP16 - GlobeNewswire
Decliners Report: How volatile is Dogwood Therapeutics Inc stock2026 Market WrapUp & AI Driven Stock Movement Reports - baoquankhu1.vn
Will Dogwood Therapeutics Inc benefit from government policyCEO Change & Weekly Stock Performance Updates - baoquankhu1.vn
Investment Report: Will Dogwood Therapeutics Inc benefit from geopolitical trends2026 Institutional & Breakout Confirmation Trade Signals - baoquankhu1.vn
Published on: 2026-04-11 05:48:42 - baoquankhu1.vn
Activity Recap: Is Dogwood Therapeutics Inc stock showing strong momentum2026 Breakouts & Breakdowns & Smart Investment Allocation Tips - baoquankhu1.vn
Is Dogwood (DWTX) Stock in a Downtrend | Price at $2.22, Up 5.21%Community Watchlist - Newser
Performance Recap: How sensitive is Dogwood Therapeutics Inc to inflationEarnings Summary Report & Proven Capital Preservation Methods - baoquankhu1.vn
Aug Weekly: Should I invest in Dogwood Therapeutics Inc before earnings2026 Key Lessons & Risk Controlled Swing Alerts - baoquankhu1.vn
Downgrade Watch: How sensitive is Dogwood Therapeutics Inc to inflationMarket Sentiment Summary & AI Enhanced Trading Signals - baoquankhu1.vn
Sentiment Watch: What is the PEG ratio of Dogwood Therapeutics IncCEO Change & Smart Allocation Stock Tips - baoquankhu1.vn
Dogwood Therapeutics Reports Q1 2026 Progress: Advances in Halneuron® and SP16 for Cancer-Related Pain and Neuropathy, $12.5M Raised - Minichart
Analysts Issue Forecasts for DWTX Q1 Earnings - Defense World
Dogwood Therapeutics Highlights Pipeline Progress and Extended Runway - TipRanks
Dogwood Therapeutics (NASDAQ: DWTX) details non-opioid pain pipeline in Q1 2026 update - Stock Titan
Q1 Earnings Estimate for DWTX Issued By Zacks Research - MarketBeat
DWTX: 143 Patients Enrolled in Phase 2b Trial of Halneuron Results Expected in 3Q26 - Research Tree
DWTX: 143 Patients Enrolled in Phase 2b Trial of Halneuron®; Results Expected in 3Q26 - Yahoo Finance
US Market Recap: What is the long term forecast for Dogwood Therapeutics Inc stockWeekly Profit Recap & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Dogwood Therapeutics (DWTX) to Release Quarterly Earnings on Monday - MarketBeat
HC Wainwright Issues Positive Forecast for DWTX Earnings - MarketBeat
If You Invested $1,000 in Dogwood Therapeutics (DWTX) - Stock Titan
History Review: Will Dogwood Therapeutics Inc benefit from government policyTrade Performance Summary & Low Risk High Win Rate Picks - baoquankhu1.vn
Aug Decliners: Will Dogwood Therapeutics Inc benefit from government policyPortfolio Profit Report & Daily Chart Pattern Signals - baoquankhu1.vn
What is HC Wainwright’s Estimate for DWTX FY2030 Earnings? - Defense World
What is HC Wainwright's Estimate for DWTX FY2030 Earnings? - MarketBeat
Performance Recap: Is Dogwood Therapeutics Inc stock showing strong momentum - baoquankhu1.vn
Maxim Group Maintains Dogwood Therapeutics(DWTX.US) With Buy Rating, Maintains Target Price $15 - Moomoo
H.C. Wainwright Maintains Dogwood Therapeutics(DWTX.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Dogwood Therapeutics 2025 Annual Report – Pipeline, Clinical Progress, Intellectual Property, and Risks in Neuropathic Pain Drug Development - Minichart
Dogwood Therapeutics (DWTX) Q4 Loss Narrows to $0.26, Beats Estimates - AlphaStreet
Moving Averages: Is Dogwood Therapeutics Inc stock showing strong momentum2026 Short Interest & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Dogwood Therapeutics (DWTX) details Halneuron pain program and going-concern risk - Stock Titan
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
DWTX: Halneuron® Phase 2b trial advances, with funding secured through key 2026 milestones - TradingView
Dogwood Therapeutics Inc Stock (DWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):